Findings

What do systematic reviews say?

14 questions · 14 findings · 1 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 11 · 78.6%GRADE not reported 0 · 0%Very low 3 · 21.4%Low 0 · 0%Moderate 0 · 0%High 0 · 0%

Short‐acting inhaled muscarinic antagonists vs placebo

Exacerbations · adults and children with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Short‐acting inhaled bronchodilators for cystic fibrosis 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Short‐acting inhaled muscarinic antagonists vs placebo

Participant‐reported symptom score Â · adults and children with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Short‐acting inhaled bronchodilators for cystic fibrosis 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Short‐acting inhaled muscarinic antagonists vs placebo

Adverse events Â · adults and children with cystic fibrosis

1 finding from 1 review

Short‐acting inhaled bronchodilators for cystic fibrosis 2022 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 27 participants
Very low

Short‐acting inhaled muscarinic antagonists vs placebo

FVC (% predicted) Change from baseline · adults and children with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Short‐acting inhaled bronchodilators for cystic fibrosis 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Short‐acting inhaled muscarinic antagonists vs placebo

Sputum: volume · adults and children with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Short‐acting inhaled bronchodilators for cystic fibrosis 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Short‐acting inhaled muscarinic antagonists vs placebo

FEV1 % predicted: absolute change from baseline · adults and children with cystic fibrosis

It is very uncertain whether short‐acting inhaled muscarinic antagonists changes change from baseline in FEV1 (% predicted) compared with placebo (very low certainty).

1 finding from 1 review

Short‐acting inhaled bronchodilators for cystic fibrosis 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 11 participants
Very low

Short‐acting inhaled muscarinic antagonists vs placebo

Quality of life Â · adults and children with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Short‐acting inhaled bronchodilators for cystic fibrosis 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Short‐acting inhaled beta‐2 agonists vs short‐acting inhaled muscarinic antagonists

FEV1 % predicted: absolute change from baseline · adults and children with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Short‐acting inhaled bronchodilators for cystic fibrosis 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Short‐acting inhaled beta‐2 agonists vs short‐acting inhaled muscarinic antagonists

Quality of life Â · adults and children with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Short‐acting inhaled bronchodilators for cystic fibrosis 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Short‐acting inhaled beta‐2 agonists vs short‐acting inhaled muscarinic antagonists

Exacerbations · adults and children with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Short‐acting inhaled bronchodilators for cystic fibrosis 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Short‐acting inhaled beta‐2 agonists vs short‐acting inhaled muscarinic antagonists

Participant‐reported symptom score Â · adults and children with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Short‐acting inhaled bronchodilators for cystic fibrosis 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Short‐acting inhaled beta‐2 agonists vs short‐acting inhaled muscarinic antagonists

Adverse events Â · adults and children with cystic fibrosis

1 finding from 1 review

Short‐acting inhaled bronchodilators for cystic fibrosis 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 17 participants
Very low

Short‐acting inhaled beta‐2 agonists vs short‐acting inhaled muscarinic antagonists

FVC (% predicted) Change from baseline · adults and children with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Short‐acting inhaled bronchodilators for cystic fibrosis 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Short‐acting inhaled beta‐2 agonists vs short‐acting inhaled muscarinic antagonists

Sputum: volume · adults and children with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Short‐acting inhaled bronchodilators for cystic fibrosis 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found